Chancellor Reeves Intends Targeted Measures on Living Costs in Upcoming Financial Plan

Chancellor Rachel Reeves has stated she is preparing "targeted action to tackle cost of living issues" in next month's financial statement.

During an interview with the BBC, she emphasized that lowering inflation is a collective duty of both the government and the Bank of England.

The UK's price growth is forecast to be the most elevated among the Group of Seven industrialized countries this year and next.

Possible Utility Bill Measures

It is understood the government could take action to reduce energy bills, such as by reducing the current 5% rate of value-added tax charged on energy.

Another option is to cut some of the government charges presently added to bills.

Budgetary Limitations and Expert Expectations

The government will receive the next assessment from the independent fiscal watchdog, the Office for Budget Responsibility, on the start of the week, which will clarify how much room there is for such measures.

The expectation from most economists is that the Chancellor will have to announce higher taxes or expenditure reductions in order to fulfill her voluntary debt limits.

Previously on Thursday, analysis indicated there was a twenty-two billion pound deficit for the chancellor to resolve, which is at the lower end of forecasts.

"There's a shared responsibility between the central bank and the government to bear down further on some of the sources of price increases," Reeves informed reporters in Washington, at the conferences of the International Monetary Fund and World Bank.

Revenue Pledges and Global Issues

While much of the attention has been on likely tax rises, the Treasury chief said the latest data from the OBR had not changed her commitment to campaign commitments not to raise tax levels on earnings tax, sales tax or social security contributions.

She blamed an "unpredictable world" with growing international and trade concerns for the fiscal revenue measures, probably to be targeted on those "with the broadest shoulders."

International Economic Tensions

Commenting on apprehensions about the UK's trade ties with the Asian nation she said: "Our national security invariably are paramount."

Last week's announcement by Chinese authorities to tighten export controls on rare earths and other materials that are essential for high-technology manufacturing led US President Donald Trump to threaten an further 100% tariff on imports from the Asian country, increasing the risk of an all-out commercial conflict between the two global powers.

The American finance chief called China's decision "commercial pressure" and "a global supply chain power grab."

Asked about considering the US offer to join its dispute with China, the Chancellor said she was "very concerned" by Chinese actions and urged the Chinese government "not to put up barriers and restrict access."

She said the decision was "damaging for the international commerce and creates further headwinds."

"I believe there are sectors where we need to address Chinese policies, but there are also important chances to trade with Chinese markets, including financial services and other areas of the economy. We've got to get that equilibrium correct."

The chancellor also affirmed she was working with G7 counterparts "regarding our own essential resources strategy, so that we are reduced dependence."

NHS Medicine Pricing and Investment

The Chancellor also recognized that the cost the National Health Service pays for pharmaceuticals could go up as a consequence of ongoing discussions with the US government and its pharmaceutical firms, in exchange for reduced taxes and funding.

Some of the world's largest pharmaceutical manufacturers have said recently that they are either delaying or canceling operations in the UK, with some blaming the insufficient payments they are obtaining.

Last month, the government science advisor said the cost the NHS pays for medicines would have to rise to prevent firms and pharmaceutical investment leaving the UK.

Reeves informed media: "It has been observed as a result of the payment system, that medical research, recent pharmaceuticals have not been provided in the UK in the extent that they are in other EU nations."

"Our aim is to make sure that patients receiving treatment from the NHS are can receive the best critical drugs in the globe. And so we are examining these issues, and... looking to attract additional capital into the UK."